Back to Search Start Over

European Commission approves AbbVie's Skyrizifor to treat adults with active psoriatic arthritis

Source :
PharmaBiz. November 18, 2021
Publication Year :
2021

Abstract

AbbVie announced that the European Commission (EC) has approved Skyrizi (risankizumab, 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination with [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
PharmaBiz
Publication Type :
Periodical
Accession number :
edsgcl.682994648